

## Specialty Packaging

On-site specialty packaging is available.


- Analytical method development
- Sample packaging
- Tertiary packaging for bundles, displays and promotions
- Many formats available



## Clinical Supplies Packaging

GMS Mississauga can provide end to end, on-time and made-to-order clinical trial supplies.

- Analytical method development
- Specialized knowledge in procurement, clinical supplies packaging design, clinical trial IT systems, inventory management including cold chain and Good Manufacturing Practices and regulations
- Diverse skill-set with multiple trial type capabilities
- Secondary packaging, ambient and cold storage and distribution facilities



Automated Storage and Retrieval System on site enables fast, calculated processes

## GMS Mississauga GlaxoSmithKline Canada

www.gsk.ca  
7333 Mississauga Road  
Mississauga, Ontario  
L5N 6L4

### Key Contacts:

**Roberto Laurignano, Manager Business Development**  
Phone: 905.819.3294  
Email: roberto.a.laurignano@gsk.com

**Darrell Black, Director Supply Chain and Strategy**  
Phone: 905.819.7170  
Email: darrell.a.black@gsk.com



**Global Manufacturing & Supply  
Mississauga, Canada**

## Product and Service Information Guide



**Experts in dermatologicals,  
liquids, solid dose and  
aerosol product capability**

*DO MORE FEEL BETTER LIVE LONGER*




## Welcome to GSK Mississauga

Since opening the Canadian Manufacturing site in 1997, GSK's Mississauga location has grown and developed to meet global demand & now produces many presentations across several dose forms including foams, solid oral dose for tablets and capsules, liquids and dermatologicals, and delivers to more than 120 markets around the world. As part of the Global Manufacturing and Supply Division of GSK, Mississauga conducts business in pharmaceutical development, manufacturing, packaging and clinical studies.

Conveniently located 15 km from Toronto International Airport, GSK Mississauga is approved by all major regulatory agencies including FDA, Health Canada, ANVISA, EMEA and the Japanese Ministry of Health.

GSK Mississauga puts a strong emphasis on employee health, safety, and well being, and puts high level environmental sustainability programs in place. The site is highly automated, leading to more cost effectiveness, and strictly follows the Quality Management System and current Good Manufacturing Practice.

At GSK Mississauga, Pharma and Consumer Healthcare products are all supported throughout their entire life cycle. Many of these products belong to Third Party customers who GSK Mississauga partners with to produce non-GSK items. We align ourselves with current trends to ensure growth for our future, and strive to deliver more products of value for patients.



### Dermatologicals

GSK Mississauga has extensive Dermatological capability.

- Early life cycle formulation/development and regulatory support through to commercialization including secondary clinical packaging and labeling
- Analytical method development
- Scalability from 5 to 3800 kg batch sizes under a wide range of manufacturing conditions
- Packaging options in tubes, bottles, sachets and pump tubes available in many sizes and shapes



### Foams

The new aerosol foams manufacturing and packaging facility and pilot plant can produce hydroethanolic, emollient and aqueous suspension foams, and has the capability to handle a range of products including hazardous and explosive materials.



- Early life cycle formulation/development and regulatory support through to commercialization including secondary clinical packaging and labeling
- 1 – 100 kg pilot scale manufacturing
- 500 – 3800 kg commercial manufacturing
- Developmental packaging on a lab line
- Commercial packaging 35 or 45 mL cans, other sizes available with change parts
- Analytical method development

### Liquids

GSK Mississauga can produce oral liquids in solutions or suspensions, as well as clean intranasal liquids.

- Early life cycle formulation/development and regulatory support through to commercialization including secondary clinical packaging and labeling
- Manufacturing batch sizes from 600 – 3000 L
- Flammable and non-flammable manufacturing and packaging capability
- Packaging available in 5 mL – 1 L plastic or glass containers
- Sachet sample packaging and robotic placement of syringes, spoons and dosing cups
- Analytical method development



### Solid Dose Tablets

- Early to late product life cycle support
- Dry, wet or spray granulation
- Direct compression
- Bi-layer tablets
- Bottles, blisters or bulk tablets for local packaging
- High sheer wet granulation
- Analytical method development



### Solid Dose Capsules

- Early to late product life cycle support
- One or two stage filling
- Powder for reconstitution/oral suspension
- Bottles, blisters or bulk capsules for local packaging
- Analytical method development